Continuing the Ascent: Q322 US Surgical Matrices Market Recap

Biosynthetic hernia matrices continue their ascent and Xenograft hernia matrices grow, thanks to TELA Bio.

As elective surgical procedures settle into pre-pandemic levels, the US Surgical Matrices Market resumed trends that had begun prior to Q322, gaining +2.4% YoY according to SmartTRAK Financial Dashboard. AbbVie* and Becton Dickinson* (BD) have been trading share positions in the last few quarters and now once again AbbVie has first place in the Q322 Surgical Matrices market despite of a -5.4% YoY decline, with BD In second place.

Among the many topics covered in detail in our comprehensive Q322 US Surgical Matrices Market Recap* are:

• Complete Q322 US Surgical Matrices Market Overview and Highlights
• SmartTRAK's Expert Market Analysis and Insights
• All Company News, Revenues, Data, Charts and Shares
• US Surgical Matrices Market Shuffles Leadership
• US Breast Matrices: Taking Advantage Of AbbVie’s Declines
• US Hernia Repair Matrices Market: A Solid Quarter
• Important Q322 US Surgical Matrices Events

The Q322 US Surgical Matrices Market grew, with more strength in the Hernia Matrices segment due to the continued growth of biosynthetic matrices Medtronic’s* ProGrip* and TELA Bio’s* OviTex* as physicians use them for more indications. In Q322, Breast Matrices’ revenue decreased as the market struggled to work around ...

Read the entire Q322 US Surgical Matrices Market Recap, including SmartTRAK's expert analysis, news, data, charts, company revenues and shares*

*These links and the complete unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.